Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single-center retrospective cohort study.
Aged
Antineoplastic Agents, Immunological
/ therapeutic use
Cetuximab
/ therapeutic use
Combined Modality Therapy
ErbB Receptors
/ antagonists & inhibitors
Female
Humans
Male
Middle Aged
Mouth Neoplasms
/ drug therapy
Retrospective Studies
Risk
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Treatment Outcome
Cetuximab
Major risk
Oral squamous cell carcinoma
Postsurgical treatment
Preemptive postsurgical therapy
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
26
11
2020
accepted:
01
01
2021
pubmed:
16
1
2021
medline:
15
2
2022
entrez:
15
1
2021
Statut:
ppublish
Résumé
A retrospective cohort study was performed to investigate the effectiveness of preemptive postsurgical therapy with cetuximab for patients with a major risk of recurrence or metastasis after clinical complete resection of primary oral squamous cell carcinoma (OSCC). The study period was from 2007 to 2019 for patients treated at the Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine. OSCC patients with major risk (n = 88) in the follow-up period were divided into groups with no postsurgical treatment (NP group), with standard postsurgical treatment (SP group), and with postsurgical treatment including cetuximab (CP group), and prognosis were compared among those groups. The 5-year overall survival rate was significantly higher in patients who received postsurgical treatment with cetuximab (CP) compared to that in the other two groups ((CP vs. NP, p = 0.028; CP vs. SP, p = 0.042). Furthermore, we performed multivariate analysis to evaluate the effects of the main components of the treatment. Among CDDP, radiotherapy, and cetuximab, only cetuximab significantly contributed to improved survival by univariate analysis (crude HR:0.228, 95%CI:0.05-0.968, p = 0.045). cetuximab also showed the same tendency in multivariate analysis, although p value did not reach significant level (Adjusted HR: 0.233, 95%CI: 0.053-1.028, p = 0.054). The results suggest that the postsurgical treatment with cetuximab as a preemptive postsurgical therapy after complete surgical resection of a visible tumor is considerably effective for OSCC patients with major risk, in other words, invisible dormant metastasis.
Identifiants
pubmed: 33449240
doi: 10.1007/s10637-021-01062-0
pii: 10.1007/s10637-021-01062-0
pmc: PMC8068704
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
846-852Références
National Comprehensive Cancer Network. NCCN Guidelines for Head and Neck Cancers (Version2.2020). Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . Accessed 24 Aug 2020
Yamamoto E, Kohama G (1983) Mode of invasion, bleomycin sensitivility and clinical course in squamous cell carcinoma of the oral cavity. Cancer 51:2175–2180
doi: 10.1002/1097-0142(19830615)51:12<2175::AID-CNCR2820511205>3.0.CO;2-M
Yamamoto E, Miyakawa A, Kohama G (1984) Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck 6:938–947
doi: 10.1002/hed.2890060508
Izumo T, Yagishita H, Yagihara K (2012) Yamamoto-Kohama classification for the clinical classification of oral cancer. J Jpn Soc Oral Tumor 24:64–76
doi: 10.5843/jsot.24.64
Onishi A, Nakashiro Ki, Mihara M, Sumida T, Kawamata H, Shintani S, Aida T, Tachikawa T, Hamakawa H (2004) Basic and clinical studies on quantitative analysis of lymph node micrometastasis in oral cancer. Oncol Rep 11:33–29
pubmed: 14654899
Uchida D, Kawamata H, Omotehara F, Nakashiro Ki, Kimura-Yanagawa T, Hino S, Begum NM, Hoque MO, Yoshida H, Sato M, Fujimori T (2001) Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93:489–496
doi: 10.1002/ijc.1368
Uchida D, Kawamata H, Nakashiro K, Omotehara F, Hino S, Hoque MO, Begum NM, Yoshida H, Sato M, Fujimori T (2001) Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines. Br J Cancer 85:122–128
doi: 10.1054/bjoc.2001.1862
Kawamata H, Uchida D, Nakashiro K, Hino S, Omotehara F, Yoshida H, Sato M (1999) Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients. Br J Cancer 80:448–452
doi: 10.1038/sj.bjc.6690377
Kawamata H, Uchida D, Hamano H, Kimura-Yanagawa T, Nakashiro KI, Hino S, Omotehara F, Yoshida H, Sato M (1998) Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 13:699–704
pubmed: 9735398
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328:184–194
doi: 10.1056/NEJM199301213280306
Sawatani Y, Komiyama Y, Nakashiro K, Uchida D, Fukumoto C, Shimura M, Hasegawa T, Kamimura R, Hitomi-Koide M, Hyodo T, Kawamata H (2020) Paclitaxel potentiates the anticancer effect of cetuximab by enhancing antibody-dependent cellular cytotoxicity on oral squamous cell carcinoma cells in vitro. Int J Mol Sci 21:E6292
doi: 10.3390/ijms21176292
Brierley DJ, Gospodarowicz KM, Wittekind C (2017) TNM Classification of Malignant Tumours, 8th edn. Wiley-Blackwell, London
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
doi: 10.1056/NEJMoa0802656
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578
doi: 10.1056/NEJMoa053422
Nishimura G, Shiono O, Sano D, Yabuki K, Arai Y, Chiba Y, Tanabe T, Oridate N (2017) Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan. Cancer Chemother Pharmacol 80:203–207
doi: 10.1007/s00280-017-3352-3
Nishimura G, Hatakeyama H, Shiono O, Taguri M, Komatsu M, Sano S, Sakuma N, Yabuki K, Arai Y, Shibata K et al (2018) Postoperative bio-chemoradiotherapy using cetuximab and docetaxel in patients with cis-platinum-intolerant core high-risk head and neck cancer: protocol of a phase 2 nonrandomized clinical trial. JMIR Res Protoc 7:e11003
doi: 10.2196/11003
Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, Goulart B, Lee S, antana-Davila R, Liao J et al (2016) Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. Head Neck 38:1318–1323
doi: 10.1002/hed.24437
Palmer JD, Schneider CJ, Hockstein N, Hanlon AL, Silberg J, Strasser J, Mauer EA, Dzeda M, Witt R, Raben A (2018) Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis. Oral Oncol 78:102–107
doi: 10.1016/j.oraloncology.2018.01.015
Kawamata H, Kameyama S, Nan L, Kawai K, Oyasu R (1993) Effect of epidermal growth factor and transforming growth factor beta 1 on growth and invasive potentials of newly established rat bladder carcinoma cell lines. Int J Cancer 55:968–973
doi: 10.1002/ijc.2910550616
Shintani S, Matsuo K, Crohin CC, McBride J, Tsuji T, Donoff RB, Posner M, Todd R, Wong DT (1999) Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res 59:4142–4147
pubmed: 10463620
Kiyota A, Shintani S, Mihara M, Nakahara Y, Ueyama Y, Matsumura T, Todd R, Wong DT (2000) Expression of a truncated epidermal growth factor receptor in oral squamous cell carcinomas. Cancer Lett 161:9–15
doi: 10.1016/S0304-3835(00)00573-5
Kamata N, Chida K, Rikimaru K, Horikoshi M, Enomoto S, Kuroki T (1986) Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. Cancer Res 46:1648–1653
pubmed: 3004701
Kawamata H, Hattori K, Omotehara F, Uchida D, Hino S, Sato M, Oyasu R (1999) Balance between activated-STAT and MAP kinase regulates the growth of human bladder cell lines after treatment with epidermal growth factor. Int J Oncol 15:661–667
pubmed: 10493946
Trivedi S, Srivastava RM, Concha-Benavente C, Ferrone S, Garcia-Bates TM, Li J, Ferris RL (2016) Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients. Clin Cancer Res 22:5229–5237
doi: 10.1158/1078-0432.CCR-15-2971